Thymosin β4 Protein Therapy for Cardiac Repair

Author(s): Karina N. Dube, Sveva Bollini, Nicola Smart, Paul R. Riley

Journal Name: Current Pharmaceutical Design

Volume 18 , Issue 6 , 2012

Become EABM
Become Reviewer
Call for Editor


Clinical interventions leading to improved survival in patients with acute myocardial infarction have, paradoxically, increased the need for cardiac regenerative strategies as more people are living with heart failure. Over the last 10-15 years there have been significant advances in our understanding of cell-based therapy for cardiac repair. Evidence that paracrine stimulation largely underlies the functional benefits in cell transplantation has led to a paradigm shift in regenerative medicine: from cell therapy to factor/protein-based therapy. Although, future regenerative approaches may likely involve a synergistic protein cocktail, this review will focus on the role of a promising candidate, thymosin beta 4 (Tβ4) in cardioprotection, neovascularization, tissue regeneration and inflammation - all essential components in cardiac repair.

Keywords: Thymosin Beta 4, Cardiovascular Disease, Regenerative Medicine, Paracrine Effect, Drug Delivery, neovascularization, zebrafish, microenvironment, matrix metalloproteinases (MMPs), phagocytic

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2012
Published on: 01 March, 2012
Page: [799 - 806]
Pages: 8
DOI: 10.2174/138161212799277699
Price: $65

Article Metrics

PDF: 9